Stoke Therapeutics, Inc. (NASDAQ: STOK), a prominent player in the biotechnology sector, has been catching the eyes of investors, boasting a market capitalization of $1.96 billion. This early-stage biopharmaceutical innovator is pioneering the development of treatments for severe genetic diseases through its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. Its focus lies in upregulating protein expression, a novel approach that holds significant promise in addressing genetic disorders.

Currently trading at $34.37, Stoke Therapeutics’ stock has experienced a robust price change of 0.11%, reflecting investor confidence in its growth trajectory. The 52-week range of $5.90 to $35.60 highlights the…